Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $87.1429.
A number of brokerages recently issued reports on ESTA. Stephens increased their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research report on Friday, March 27th. Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a research report on Wednesday, May 6th. BTIG Research increased their target price on shares of Establishment Labs from $88.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, Needham & Company LLC increased their target price on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th.
Check Out Our Latest Report on Establishment Labs
Insider Transactions at Establishment Labs
Hedge Funds Weigh In On Establishment Labs
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Nantahala Capital Management LLC grew its position in Establishment Labs by 11.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock valued at $80,893,000 after buying an additional 197,962 shares in the last quarter. Bamco Inc. NY boosted its position in shares of Establishment Labs by 30.2% during the 3rd quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock valued at $48,443,000 after purchasing an additional 274,287 shares in the last quarter. Tyro Capital Management LLC boosted its position in shares of Establishment Labs by 1.0% during the 3rd quarter. Tyro Capital Management LLC now owns 1,077,456 shares of the company’s stock valued at $44,165,000 after purchasing an additional 10,735 shares in the last quarter. William Blair Investment Management LLC boosted its position in shares of Establishment Labs by 17.6% during the 3rd quarter. William Blair Investment Management LLC now owns 1,017,543 shares of the company’s stock valued at $41,709,000 after purchasing an additional 152,299 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of Establishment Labs by 117.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock valued at $59,145,000 after purchasing an additional 438,206 shares in the last quarter. Institutional investors own 72.91% of the company’s stock.
Establishment Labs Trading Up 1.3%
Shares of NASDAQ:ESTA opened at $72.19 on Tuesday. The company has a market cap of $2.12 billion, a PE ratio of -48.45 and a beta of 1.12. The company’s 50-day moving average price is $64.59 and its 200 day moving average price is $67.94. Establishment Labs has a fifty-two week low of $33.35 and a fifty-two week high of $83.31. The company has a quick ratio of 1.91, a current ratio of 2.96 and a debt-to-equity ratio of 16.82.
Establishment Labs (NASDAQ:ESTA – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The firm had revenue of $59.88 million during the quarter, compared to the consensus estimate of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The company’s revenue for the quarter was up 44.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.70) earnings per share. Sell-side analysts anticipate that Establishment Labs will post -1.07 earnings per share for the current year.
About Establishment Labs
Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.
The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.
Featured Stories
- Five stocks we like better than Establishment Labs
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.
